The iShares Biotechnology ETF (IBB) closed at $210.81 on August 21, 2026, posting a decline of 2.86% over the prior 24 hours. The single-day drop erased a portion of recent gains but left the fund significantly higher compared to earlier timeframes.
Over the past seven days, IBB advanced 5.97%, reflecting a broader stretch of buying interest in the biotechnology sector. The 30-day gain of 11.42% underscores a more sustained period of strength leading into Friday's session.
The daily pullback stands in contrast to the fund's longer-term trajectory. While short-term volatility is common in sector-focused ETFs, IBB's 30-day performance places it well above where it traded a month ago.
Market capitalization data was not available for IBB at the time of publication. The fund tracks a broad index of U.S.-listed biotechnology companies, making it a widely watched gauge of sentiment across the sector.
